EligibleTrials

Doxycycline: clinical trials recruiting now

3
Recruiting trials
15
Conditions studied
1
US states with sites
4
Countries

FDA drug label

FDA-approved
Yes. Doxycycline appears in the FDA drug-label database. Marketed as DOXYCYCLINE.
Drug class
Tetracycline-class Drug (FDA established pharmacologic class)

FDA-approved use

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nong…

FDA recalls / enforcement

Reason (FDA)ClassificationStatusInitiated
Failed dissolution specification: The dissolution test at the 24 month time point (end of shelf life) yielded an out of specification result. — West-Ward Columbus Inc Class II (FDA: may cause temporary or reversible harm) Terminated 2020-05-13
Failed Dissolution Specifications: — West-Ward Columbus Inc Class II (FDA: may cause temporary or reversible harm) Terminated 2018-07-24
Failed Dissolution Specifications: — West-Ward Columbus Inc Class II (FDA: may cause temporary or reversible harm) Terminated 2018-07-24
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions. — CARDINAL HEALTHCARE Class II (FDA: may cause temporary or reversible harm) Terminated 2022-01-26
CGMP Deviations: Doxycycline capsules were not manufactured under Current Good Manufacturing Practice conditions. — Sun Pharmaceutical Industries, Inc. Class II (FDA: may cause temporary or reversible harm) Terminated 2020-03-13

FDA label via openFDA

Phase breakdown

Phase 2 1 Phase 3 1 Not applicable 1

Conditions being studied

ConditionTrials
Acute Coronary Syndrome1
Chlamydia Infections1
Dermatitis1
Dermatitis, Atopic1
Eczema1
Gonorrhea1
HIV1
HIV Infections1
Hypertension1
Pulmonary Hypertension (Diagnosis)1
Sexually Transmitted Diseases1
Skin Diseases1
Skin Diseases, Genetic1
Syphilis1
Tuberculosis1

Recruiting trials involving Doxycycline

Common questions

Is Doxycycline FDA-approved?

Yes, marketed as DOXYCYCLINE.

How many recruiting trials involve Doxycycline?

3 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.